Cardiovascular outcomes in de novo Kidney transplant recipients receiving everolimus and reduced calcineurin inhibitor or standard triple therapy

• Verfasst von: Sommerer, Claudia [VerfasserIn]
• Verfasst von: Legendre, Christophe [VerfasserIn]
• Verfasst von: Citterio, Franco [VerfasserIn]
• Verfasst von: Watarai, Yoshihiko [VerfasserIn]
• Verfasst von: Oberbauer, Rainer [VerfasserIn]
• Verfasst von: Basic-Jukic, Nikolina [VerfasserIn]
• Verfasst von: Han, Jackie [VerfasserIn]
• Verfasst von: Gawai, Apurva [VerfasserIn]
• Verfasst von: Bernhardt, Peter [VerfasserIn]
• Verfasst von: Chadban, Steve [VerfasserIn]
• Titel: Cardiovascular outcomes in de novo Kidney transplant recipients receiving everolimus and reduced calcineurin inhibitor or standard triple therapy
• Titelzusatz: 24-month post hoc analysis from TRANSFORM study
• Verf.angabe: Claudia Sommerer, Christophe Legendre, Franco Citterio, Yoshihiko Watarai, Rainer Oberbauer, Nikolina Basic-Jukic, Jackie Han, Apurva Gawai, Peter Bernhardt, and Steve Chadban
• E-Jahr: 2023
• Jahr: July 2023
• Umfang: 12 S.
• Fussnoten: Gesehen am 09.01.2024
• Titel Quelle: Enthalten in: Transplantation
• Ort Quelle: Hagerstown, Md. : Lippincott Williams & Wilkins, 1963
• Jahr Quelle: 2023
• Band/Heft Quelle: 107(2023), 7, Seite 1593-1604
• ISSN Quelle: 1534-6080
• DOI: doi:10.1097/TP.0000000000004555
• Datenträger: Online-Ressource
• Sprache: eng
• K10plus-PPN: 1877495301

Abstract

Background. - The comparative impact of everolimus (EVR)-based regimens versus standard of care (mycophenolic acid+standard calcineurin inhibitor [MPA+sCNI]) on cardiovascular outcomes in de novo kidney transplant recipients (KTRs) is poorly understood. The incidence of major adverse cardiac events (MACEs) in KTRs receiving EVR+reduced CNI (rCNI) or MPA+sCNI from the TRANSplant eFficacy and safety Outcomes with an eveRolimus-based regiMen study was evaluated. - Methods. - The incidence of MACE was determined for all randomized patients receiving at least 1 dose of the study drug. Factors associated with MACEs were determined by logistic regression. Risk of MACE out to 3 y post-study was calculated using the Patient Outcome in Renal Transplantation equation. - Results. - MACE occurred in 81 of 1014 (8.0%; EVR+rCNI) versus 89 of 1012 (8.8%; MPA+sCNI) KTRs (risk ratio, 0.91 [95% confidence interval [CI], 0.68-1.21]). The incidence of circulatory death, myocardial infarction, revascularization, or angina was similar between the arms. Incidence of MACE was similar between EVR+rCNI and MPA+sCNI arms with a higher incidence in prespecified risk groups: older age, pretransplant diabetes (15.1% versus 15.9%), statin use (8.5% versus 10.8%), and low estimated glomerular filtration rate (Month 2 estimated glomerular filtration rate <30 versus >60 mL/min/1.73 m2; odds ratio, 2.23 [95% CI, 1.02-4.86]; P = 0.044), respectively. Predicted risk of MACE within 3 y of follow-up did not differ between the treatment arms. - Conclusions. - Cardiovascular morbidity and mortality were similar between de novo KTRs receiving EVR+rCNI and MPA+sCNI. EVR+rCNI is a viable alternative to the current standard of care in KTRs. - - - - - Export